Top

Published in:

01-09-2017 | Case report

Ibrutinib

Bruising: case report

Published in: Reactions Weekly | Issue 1/2017

Excerpt

In a case series of 5 patients, a 54-year-old man was described, who developed bruising during treatment with oral ibrutinib 560 mg/day, for stage IV mantle cell lymphoma with leptomeningeal central nervous system lesion [time to reaction onset and outcome not stated]. He was also receiving high-dose methotrexate with rituximab and high-dose cytarabine concomitantly, and concurrently, he also had significant thrombocytopenia related to bone marrow failure. …

Tucker DL, et al. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom. British Journal of Haematology 178: 327-329, No. 2, Jul 2017. Available from: URL: http://doi.org/10.1111/bjh.14122 - UnitedKingdomCrossRefPubMed

Title: Ibrutinib
Bruising: case report
Publication date: 01-09-2017
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2017
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-017-35678-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ibrutinib

Bruising: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

Antituberculars

Phenytoin

Warfarin

Mycophenolate mofetil/prednisone/tacrolimus

Paracetamol/diphenhydramine overdose

Metformin